Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15173760 | 0.86 | KEAP1 (0.54) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E | |
| SCHEMBL15173940 | 0.85 | KEAP1 (0.52) | ALDH1A1SMN1; SMN2KEAP1KDM4ECYP1A2 | |
| SCHEMBL15173887 | 0.83 | SMN1; SMN2 (0.50) | ALDH1A1SMN1; SMN2KEAP1KDM4ECYP1A2 | |
| SCHEMBL20635073 | 0.81 | GLA (0.40) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E | |
| SCHEMBL646005 | 0.80 | KDM4E (0.50) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E | |
| SCHEMBL235080 | 0.79 | KDM4E (0.65) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E | |
| SCHEMBL27160143 | 0.77 | ALDH1A1 (0.43) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E | |
| SCHEMBL10379098 | 0.77 | — | — | |
| SCHEMBL21623672 | 0.76 | KDM4E (0.46) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E | |
| SCHEMBL5345779 | 0.76 | KDM4E (0.46) | GLAALDH1A1SMN1; SMN2KEAP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | ARBOR PHARMACEUTICALS, LLC | 2021-07-29 | — | — | US | claimed |
| WO-2020015716-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2020-01-23 | — | — | WO | claimed |
| US-9302977-B2 | Method of making monomethyl fumarate | XENOPORT, INC. (US) | 2016-04-05 | — | — | US | claimed |
| EP-2887934-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XenoPort, Inc. (US) | 2015-07-01 | — | — | EP | claimed |
| EP-2854795-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XenoPort, Inc. (US) | 2015-04-08 | — | — | EP | claimed |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2014-12-11 | — | — | US | claimed |
| WO-2014197860-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | XENOPORT, INC. (US) | 2014-12-11 | — | — | WO | claimed |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-11-27 | — | — | US | claimed |
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | XENOPORT, INC. (US) | 2014-02-27 | — | — | US | claimed |
| WO-2014031844-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | XENOPORT, INC. (US) | 2014-02-27 | — | — | WO | claimed |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | WILSHIRE PHARMACEUTICALS, INC. | 2013-12-05 | — | — | US | claimed |
| WO-2013181451-A1 | TREATMENT OF MULTIPLE SCLEROSIS AND PSORIASIS USING PRODRUGS OF METHYL HYDROGEN FUMARATE | XENOPORT, INC. (US) | 2013-12-05 | — | — | WO | claimed |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT | 2024-07-18 | — | — | US | disclosed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC. | 2024-05-23 | — | — | US | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| WO-2002081433-A1 | SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
| US-4104402-A | BRONCHODILATORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1978-08-01 | — | — | US | disclosed |
| US-4035512-A | Aminotetralols | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-07-12 | — | — | US | disclosed |
| US-4010202-A | TREATMENT OF ASTHMA AND ARRHYTHMIA | TAKEDA CHEMICAL INDUSTRIES, LTD. (JA) | 1977-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057917-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | GLA 459/4885ALDH1A1 626/4885SMN1; SMN2 1509/4885 |
| US-20140350018-A9 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | GLA 459/4885ALDH1A1 626/4885SMN1; SMN2 1509/4885 |
| US-20240166669-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | KRAS, NRAS, HRAS | GLA 3936/4885ALDH1A1 3856/4885SMN1; SMN2 4249/4885 |
| US-20240240229-A1 | METHODS OF ADMINISTERING MONOMETHYL FUMARATE AND PRODRUGS THEREOF HAVING REDUCED SIDE EFFECTS | GSTM1, GSTM2, GSTA1 | GLA 528/4885ALDH1A1 635/4885SMN1; SMN2 1538/4885 |
| US-20140364604-A1 | METHOD OF MAKING MONOMETHYL FUMARATE | FH, HNMT, FPGS | GLA 1439/4885ALDH1A1 1047/4885SMN1; SMN2 125/4885 |
| US-20210228525-A1 | Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects | FH, FAH, ALDOA | GLA 459/4885ALDH1A1 626/4885SMN1; SMN2 1509/4885 |
| US-20130324539-A1 | Treatment of Multiple Sclerosis and Psoriasis Using Prodrugs of Methyl Hydrogen Fumarate | MGMT, FH, SI | GLA 2205/4885ALDH1A1 3064/4885SMN1; SMN2 1726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.